Extensive necrotizing fasciitis associated with sunitinib therapy.
University of Toronto, Leslie Dan Faculty of Pharmacy, Toronto, Canada; Vancouver Island Health Authority, Victoria, Canada. Electronic address: jolanta.piszczek@mail.utoronto.ca.
Jolanta
J
Piszczek
Pharmacy Services, Alberta Health Services, Foothills Medical Centre, Calgary, Canada.
Bruce
B
Dalton
Department of Dermatology, University of Calgary, Calgary, Canada.
Tess
T
Peters
Department of Oncology, University of Calgary, Calgary, Canada.
Dean
D
Ruether
Department of Pathology, University of Calgary, Calgary, Canada.
Stefan
S
Urbanski
D000368:Aged; D000970:Antineoplastic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D002292:Carcinoma, Renal Cell / Q000188:drug therapy; D019115:Fasciitis, Necrotizing / Q000139:chemically induced / Q000175:diagnosis* / Q000628:therapy; D016908:Gram-Positive Bacterial Infections / Q000139:chemically induced / Q000175:diagnosis* / Q000628:therapy; D006801:Humans; D007211:Indoles / Q000009:adverse effects* / Q000627:therapeutic use; D007680:Kidney Neoplasms / Q000188:drug therapy; D008297:Male; D011758:Pyrroles / Q000009:adverse effects* / Q000627:therapeutic use; D050151:Subcutaneous Fat / Q000382:microbiology / Q000473:pathology; D000077210:Sunitinib
D000970:Antineoplastic Agents; D007211:Indoles; D011758:Pyrroles; D000077210:Sunitinib
Adverse drug reaction; Fournier's gangrene; Renal cell carcinoma; Tyrosine kinase inhibitors; Vascular endothelial growth factors